Loading patent…
AssigneeBiogen Idec MA Inc.
InventorsJeffrey L. Browning, Werner Meier, Christopher D. Benjamin
Estimating the term…
This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-α and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-α/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.
An isolated anti-lymphotoxin-β-receptor (LT-β-R) antibody comprising a light chain comprising a variable domain corresponding to an antibody produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793), and a heavy chain comprising a variable domain corresponding to the antibody produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793).
An isolated anti-LT-β-R antibody comprising a light chain comprising antigen binding regions from a CB.E11.1 mouse monoclonal antibody (ATCC Accession No. HB11793), and a heavy chain comprising antigen binding regions from the CB.E11.1 mouse monoclonal antibody (ATCC Accession No. HB11793).
An isolated humanized anti-LT-β-R antibody comprising
A pharmaceutical composition comprising an anti-LT-β-R antibody comprising a light chain comprising antigen binding regions from the antibody produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793) and a heavy chain comprising antigen binding regions from the antibody produced by hybridoma CB .E 11.1 (ATCC Accession No. HB11793).
An isolated antibody produced by a hybridoma cell line having ATCC Accession No. HB11793.
Dependencies are inferred from the claim text.